OPKO Health Inc (OQ:OPK)

Business Focus: Medical & Diagnostic Laboratories

Nov 20, 2024 08:00 am ET
OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference
OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024 at the Lotte New York Palace Hotel in New York City. Management will be...
Nov 18, 2024 07:00 am ET
NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo
OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow
Nov 14, 2024 05:00 am ET
NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
Company Sees Initial Sales Momentum in China for OPKO Health Products as it Prepares for the Launch of its Florida Sunshine Brand of Vitamins and Supplements
Nov 08, 2024 04:05 pm ET
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024. “The...
Nov 07, 2024 04:05 pm ET
OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of...
Nov 07, 2024 08:00 am ET
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®
Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration...
Oct 29, 2024 04:05 pm ET
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Thursday, November 7, 2024. OPKO’s senior management will...
Oct 07, 2024 08:00 am ET
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the...
Oct 07, 2024 08:00 am ET
NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market
Sep 25, 2024 08:30 am ET
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative...
Sep 23, 2024 08:00 am ET
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug...
Sep 16, 2024 07:30 am ET
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Enhances Labcorp's laboratory services network and expands access to its clinical services 
Aug 09, 2024 04:05 pm ET
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024. “We...
Aug 07, 2024 04:06 pm ET
OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001...
Aug 01, 2024 04:05 pm ET
OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Wednesday, August 7, 2024. OPKO’s senior management will provide a...
Jul 18, 2024 08:00 am ET
OPKO Health Announces $100 Million Share Repurchase Program
OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock.   Under the repurchase program, OPKO may repurchase shares of its common stock...
Jul 17, 2024 04:14 pm ET
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments
OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relating...
Jul 02, 2024 08:00 am ET
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner
New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additional E-Commerce Platforms, in Brick-and-Mortar Retail Locations and Launch In-Country Digital Marketing Programs
May 31, 2024 10:48 am ET
OPKO Health to Participate in the Jefferies Global Healthcare Conference
OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be holding one-on-one meetings...
May 07, 2024 04:05 pm ET
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of...
May 03, 2024 08:00 am ET
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update...
Mar 28, 2024 08:00 am ET
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services
Mar 20, 2024 08:00 am ET
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist...
Mar 05, 2024 08:52 am ET
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference...
Feb 27, 2024 04:05 pm ET
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from the fourth quarter and subsequent weeks included the following: ModeX advanced its...
Feb 23, 2024 08:31 am ET
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?
NEW YORK, Feb. 23, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LUNR, OPK, ARDX, AXTI, and CMND.
Feb 22, 2024 04:05 pm ET
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024. OPKO’s senior management will provide a...
Feb 05, 2024 07:00 am ET
NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China
E-Commerce Storefront to Initially Support Sales of up to 40 Personal Health and Wellness Products; Final International Certifications and Approvals Required for Formal Launch Expected This Quarter
Jan 09, 2024 04:05 pm ET
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes
OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”), which amount includes the...
Jan 08, 2024 08:00 am ET
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco. Management will be hosting...
Jan 04, 2024 11:31 pm ET
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”). The Company granted the initial purchaser in...
Jan 03, 2024 05:05 pm ET
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”). The Company also expects to grant the...
Nov 28, 2023 06:00 am ET
BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing
ELMWOOD PARK, N.J., Nov. 28, 2023 /PRNewswire/ -- BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pioneer in providing accessible, quality real world data ("RWD") for the pharmaceutical and life science industries. This collaborative arrangement will offer healthcare providers and researchers unique solutions to inform clinical studies and improve patient outcomes. Combining genetic data and critical biomarkers, means targeted precision therapies based on patients' genetic profiles will be more r
Nov 07, 2023 05:45 am ET
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country
Nov 07, 2023 05:45 am ET
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country
Nov 06, 2023 04:05 pm ET
OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights from the third quarter and subsequent weeks included the following: ModeX...
Nov 02, 2023 10:00 am ET
New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023
OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia today. These data, presented in a poster titled “Control...
Oct 31, 2023 08:00 am ET
OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U.S. financial markets on Monday, November 6, 2023. OPKO’s senior management will provide...
Oct 25, 2023 04:25 pm ET
OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023
OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023. These data will be...
Oct 12, 2023 10:50 am ET
NextPlat's Florida E-Commerce Development Program to Launch the Online Sales of OPKO Healthcare Products in China on Alibaba's Tmall Global
New E-Commerce Agreement Enables NextPlat to Offer OPKO's Nutraceutical and Veterinary Products for Sale to Chinese Consumers
Sep 29, 2023 09:31 am ET
Thinking about buying stock in Blue Apron Holdings, OceanPal, OPKO Health, Bionomics, or Aytu Biopharma?
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRN, OP, OPK, BNOX, and AYTU.
Sep 28, 2023 04:08 pm ET
ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats
ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S....
Sep 12, 2023 08:30 am ET
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary...
Aug 03, 2023 04:05 pm ET
OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023. Second quarter business highlights included the following: U.S. FDA approved NGENLA™ for pediatric growth hormone...
Jul 25, 2023 04:05 pm ET
OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. OPKO’s senior management will provide a...
Jul 14, 2023 09:31 am ET
Thinking about buying stock in Mind Medicine (MindMed), OPKO Health, Grange Resources, Hyzon Motors, or Bright Minds Biosciences?
NEW YORK, July 14, 2023  InvestorsObserver issues critical PriceWatch Alerts for MNMD, OPK, GRR, HYZN, and DRUG.
Jul 06, 2023 09:31 am ET
Thinking about buying stock in Lucid Group, OPKO Health, Eos Energy Enterprises, Kartoon Studios, or Allarity Therapeutics?
NEW YORK, July 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, OPK, EOSE, TOON, and ALLR.
Jun 28, 2023 09:31 am ET
Thinking about buying stock in Marinus Pharmaceuticals, OPKO Health, Xponential Fitness, Plug Power, or Asetek A/S?
NEW YORK, June 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNS, OPK, XPOF, PLUG, and ASTK.
Jun 28, 2023 06:45 am ET
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.
May 03, 2023 04:05 pm ET
OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: OPKO Health’s ModeX Therapeutics, Inc. (ModeX) entered into an...
Apr 25, 2023 04:05 pm ET
OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financial markets on Wednesday, May 3, 2023. OPKO’s senior management will provide a business...
Mar 09, 2023 08:00 am ET
OPKO Health to Hold Virtual R&D Day on March 20, 2023
OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX...
Mar 08, 2023 08:00 am ET
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
OPKO Health, Inc. (NASDAQ: OPK) today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and Canada, for the...
Feb 23, 2023 04:05 pm ET
OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2022. Business highlights include the following: Sales are underway by Pfizer for NGENLA® (somatrogon) in 15 countries...
Feb 16, 2023 11:41 am ET
OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKO’s senior management will provide a...
Feb 09, 2023 06:05 am ET
BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings
CINtec® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive
Jan 03, 2023 08:00 am ET
OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023 at the Westin St. Francis in San Francisco. Management will be hosting...
Nov 08, 2022 04:05 pm ET
OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2022. Business highlights for the third quarter of 2022 and subsequent weeks include the following: Pfizer’s NGENLA®...
Nov 01, 2022 08:00 am ET
OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2022 after the close of the U.S. financial markets on Tuesday, November 8, 2022. OPKO’s senior management will provide...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.